Fact based stock research
IDEXX (NasdaqGS:IDXX)


IDEXX stock research in summary

idexx.com


IDEXX shares have a SELL rating. While they show above average growth, they are riskily financed, and are bad value. We recommend selling IDEXX shares.


Latest Obermatt Ranks


Country USA
Industry Health Care Equipment
Index NASDAQ 100, NASDAQ, S&P 500, D.J. US Medical Equipment
Size class X-Large

February 1, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Achievements

Top 10 Stock






 

Research History: IDEXX

STOCK RESEARCH SUMMARY 2015 2016 2017 2018
STOCK VALUE RANKS
22
14
14
14
STOCK GROWTH RANKS
61
69
77
77
STOCK SAFETY RANKS
100
25
40
40
COMBINED STOCK RANKS
8
31
31
31

Last update of Combined Rank: 1-Feb-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is IDEXX in the corresponding investment strategy.


Value Metrics in Detail

Last update of Value Rank: 1-Feb-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of IDEXX; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
55
39
53
53
PROFIT GROWTH
69
47
40
40
STOCK RETURNS
28
90
89
89
CONSOLIDATED RANK: GROWTH
61
69
77
77

Financial reporting date of Growth Rank: 30-Sep-2017. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of IDEXX.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
100
1
32
32
REFINANCING
39
39
LIQUIDITY
68
70
67
67
CONSOLIDATED RANK: SAFETY
100
25
40
40

Financial reporting date of Safety Rank: 30-Sep-2017. Stock analysis on safety metrics: The higher the rank, the lower the leverage of IDEXX and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for IDEXX from February 1, 2018.